These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 22934764)

  • 21. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
    Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
    Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
    [No Abstract]   [Full Text] [Related]  

  • 26. From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.
    Ferreira LG; Andricopulo AD
    Curr Top Med Chem; 2017; 17(20):2260-2270. PubMed ID: 28240184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
    Hameed R; Khan A; Khan S; Perveen S
    Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment informatics and computational fragment-based drug design: an overview and update.
    Sheng C; Zhang W
    Med Res Rev; 2013 May; 33(3):554-98. PubMed ID: 22430881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SPR-based fragment screening: advantages and applications.
    Neumann T; Junker HD; Schmidt K; Sekul R
    Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weak affinity chromatography as a new approach for fragment screening in drug discovery.
    Duong-Thi MD; Meiby E; Bergström M; Fex T; Isaksson R; Ohlson S
    Anal Biochem; 2011 Jul; 414(1):138-46. PubMed ID: 21352794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
    Danielson UH
    Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rise of fragment-based drug discovery.
    Murray CW; Rees DC
    Nat Chem; 2009 Jun; 1(3):187-92. PubMed ID: 21378847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fragment-based screening with natural products for novel anti-parasitic disease drug discovery.
    Liu M; Quinn RJ
    Expert Opin Drug Discov; 2019 Dec; 14(12):1283-1295. PubMed ID: 31512943
    [No Abstract]   [Full Text] [Related]  

  • 39. Fragment-based approach to drug lead discovery: overview and advances in various techniques.
    Fattori D; Squarcia A; Bartoli S
    Drugs R D; 2008; 9(4):217-27. PubMed ID: 18588353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.